Agilent Technologies Inc. (A)
NYSE: A
· Real-Time Price · USD
138.69
0.46 (0.33%)
At close: Oct 14, 2025, 1:12 PM
Agilent Revenue by End Market
| Period Ending | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmaceutical and Biopharmaceutical | 2.32B | 2.26B | 2.24B | 2.24B | 2.29B | 2.36B | 2.43B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Pharmaceutical and Biopharmaceutical Growth | +2.70% | +0.89% | +0.22% | -2.27% | -2.97% | -3.04% | -3.61% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Chemicals and Advanced Materials | 1.49B | 1.48B | 1.5B | 1.49B | 1.51B | 1.53B | 1.54B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Chemicals and Advanced Materials Growth | +0.47% | -0.87% | +0.27% | -1.45% | -1.05% | -0.91% | -2.71% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Diagnostics and Clinical | 992M | 976M | 964M | 945M | 944M | 955M | 966M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Diagnostics and Clinical Growth | +1.64% | +1.24% | +2.01% | +0.11% | -1.15% | -1.14% | -0.92% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Food | 611M | 603M | 592M | 596M | 603M | 625M | 628M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Food Growth | +1.33% | +1.86% | -0.67% | -1.16% | -3.52% | -0.48% | -2.33% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Academia and Government | 550M | 554M | 567M | 567M | 585M | 605M | 601M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Academia and Government Growth | -0.72% | -2.29% | 0.00% | -3.08% | -3.31% | +0.67% | 0.00% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Environmental and Forensics | 663M | 656M | 650M | 661M | 657M | 662M | 662M | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Environmental and Forensics Growth | +1.07% | +0.92% | -1.66% | +0.61% | -0.76% | 0.00% | -0.45% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
Revenue by Instrumentation
| Period Ending | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Instrumentation | 2.35B | 2.35B | 2.35B | 2.38B | 2.47B | 2.61B | 2.74B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Instrumentation Growth | +0.09% | -0.21% | -1.30% | -3.52% | -5.40% | -4.70% | -6.22% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Non Instrumentation and Other | 4.28B | 4.18B | 4.16B | 4.11B | 4.12B | 4.12B | 4.09B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Non Instrumentation and Other Growth | +2.22% | +0.67% | +1.07% | -0.17% | -0.07% | +0.76% | +0.52% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
Revenue by Segment
| Period Ending | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Sciences and Applied Markets Group | 2.92B | 3.02B | 3.21B | 3.31B | 3.46B | 3.67B | 3.86B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Life Sciences and Applied Markets Group Growth | -3.32% | -6.19% | -2.87% | -4.20% | -5.83% | -4.85% | -4.65% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Agilent Crosslab Group | 2.25B | 1.94B | 1.64B | 1.62B | 1.61B | 1.59B | 1.57B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Agilent Crosslab Group Growth | +16.07% | +17.70% | +1.36% | +0.93% | +0.94% | +1.53% | +1.49% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Diagnostics and Genomics Group | 1.47B | 1.58B | 1.65B | 1.56B | 1.53B | 1.47B | 1.41B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Diagnostics and Genomics Group Growth | -7.33% | -4.18% | +5.50% | +2.35% | +3.73% | +4.61% | +0.28% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
Revenue by Type
| Period Ending | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Products | 4.72B | 4.66B | 4.67B | 4.69B | 4.79B | 4.94B | 5.05B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Products Growth | +1.31% | -0.19% | -0.32% | -2.11% | -3.02% | -2.26% | -3.48% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Services and Other | 1.9B | 1.87B | 1.84B | 1.81B | 1.8B | 1.8B | 1.78B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Services and Other Growth | +1.82% | +1.74% | +1.55% | +0.39% | +0.28% | +0.90% | +1.19% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
Revenue by Geography
| Period Ending | Apr 30, 2025 | Jan 31, 2025 | Oct 31, 2024 | Jul 31, 2024 | Apr 30, 2024 | Jan 31, 2024 | Oct 31, 2023 | Jul 31, 2023 | Apr 30, 2023 | Jan 31, 2023 | Oct 31, 2022 | Jul 31, 2022 | Apr 30, 2022 | Jan 31, 2022 | Oct 31, 2021 | Jul 31, 2021 | Apr 30, 2021 | Jan 31, 2021 | Oct 31, 2020 | Jul 31, 2020 | Apr 30, 2020 | Jan 31, 2020 | Oct 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | 2.65B | 2.61B | 2.57B | 2.6B | 2.64B | 2.67B | 2.73B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Americas Growth | +1.57% | +1.52% | -0.85% | -1.56% | -1.46% | -2.09% | -0.47% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| Europe | 1.79B | 1.77B | 1.77B | 1.75B | 1.75B | 1.76B | 1.75B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| Europe Growth | +0.90% | +0.28% | +1.20% | 0.00% | -0.40% | +0.11% | +0.86% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |
| APAC | 2.18B | 2.15B | 2.17B | 2.15B | 2.21B | 2.3B | 2.35B | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade |
| APAC Growth | +1.77% | -0.97% | +0.65% | -2.40% | -4.25% | -1.83% | -6.49% | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | Upgrade | - |